 Angiotensin-Converting Enzyme Inhibitors
"Angiotensin-Converting Enzyme Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A class of drugs whose main indications are the treatment of hypertension and heart failure. They exert their hemodynamic effect mainly by inhibiting the renin-angiotensin system. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility.
| Descriptor ID |
D000806
|
| MeSH Number(s) |
D27.505.519.389.745.085
|
| Concept/Terms |
Angiotensin-Converting Enzyme Inhibitors- Angiotensin-Converting Enzyme Inhibitors
- Angiotensin Converting Enzyme Inhibitors
- Inhibitors, Kininase II
- Kininase II Antagonists
- Kininase II Inhibitors
- Angiotensin I-Converting Enzyme Inhibitors
- Angiotensin I Converting Enzyme Inhibitors
- Antagonists, Angiotensin-Converting Enzyme
- Antagonists, Angiotensin Converting Enzyme
- Antagonists, Kininase II
- Inhibitors, ACE
- ACE Inhibitors
- Inhibitors, Angiotensin-Converting Enzyme
- Enzyme Inhibitors, Angiotensin-Converting
- Inhibitors, Angiotensin Converting Enzyme
- Angiotensin-Converting Enzyme Antagonists
- Angiotensin Converting Enzyme Antagonists
- Enzyme Antagonists, Angiotensin-Converting
|
Below are MeSH descriptors whose meaning is more general than "Angiotensin-Converting Enzyme Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Angiotensin-Converting Enzyme Inhibitors".
This graph shows the total number of publications written about "Angiotensin-Converting Enzyme Inhibitors" by people in this website by year, and whether "Angiotensin-Converting Enzyme Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 | | 1996 | 1 | 0 | 1 | | 1999 | 1 | 0 | 1 | | 2001 | 2 | 0 | 2 | | 2002 | 0 | 3 | 3 | | 2003 | 1 | 0 | 1 | | 2004 | 3 | 0 | 3 | | 2005 | 1 | 0 | 1 | | 2006 | 0 | 1 | 1 | | 2007 | 2 | 0 | 2 | | 2008 | 2 | 1 | 3 | | 2009 | 1 | 2 | 3 | | 2011 | 1 | 2 | 3 | | 2012 | 0 | 1 | 1 | | 2013 | 0 | 2 | 2 | | 2020 | 1 | 1 | 2 | | 2021 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Angiotensin-Converting Enzyme Inhibitors" by people in Profiles.
-
Pan M, Vasbinder A, Anderson E, Catalan T, Shadid HR, Berlin H, Padalia K, O'Hayer P, Meloche C, Azam TU, Khaleel I, Michaud E, Blakely P, Bitar A, Huang Y, Zhao L, Pop-Busui R, Loosen SH, Chalkias A, Tacke F, Giamarellos-Bourboulis EJ, Reiser J, Eugen-Olsen J, Hayek SS. Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers, and Outcomes in Patients Hospitalized for COVID-19. J Am Heart Assoc. 2021 12 21; 10(24):e023535.
-
Agustini B, Mohebbi M, Woods RL, McNeil JJ, Nelson MR, Shah RC, Murray AM, Ernst ME, Reid CM, Tonkin A, Lockery JE, Berk M. The association of antihypertensive use and depressive symptoms in a large older population with hypertension living in Australia and the United States: a cross-sectional study. J Hum Hypertens. 2020 11; 34(11):787-794.
-
Brown SA, Okwuosa TM, Barac A, Volgman AS. The Role of Angiotensin-Converting Enzyme Inhibitors and ?-Blockers in Primary Prevention of Cardiac Dysfunction in Breast Cancer Patients. J Am Heart Assoc. 2020 01 21; 9(2):e015327.
-
Grady KL, de Leon CF, Kozak AT, Cursio JF, Richardson D, Avery E, Calvin JE, Powell LH. Does self-management counseling in patients with heart failure improve quality of life? Findings from the Heart Failure Adherence and Retention Trial (HART). Qual Life Res. 2014 Feb; 23(1):31-8.
-
Persu A, Lambert M, Deinum J, Cossu M, de Visscher N, Irenge L, Ambroise J, Minon JM, Nesterovitch AB, Churbanov A, Popova IA, Danilov SM, Danser AH, Gala JL. A novel splice-site mutation in angiotensin I-converting enzyme (ACE) gene, c.3691+1G>A (IVS25+1G>A), causes a dramatic increase in circulating ACE through deletion of the transmembrane anchor. PLoS One. 2013; 8(4):e59537.
-
Zhang QY, Li Y, Guan SY, Wang XZ, Jing QM, Ma YY, Wang G, Wang B, Deng J, Han YL. Incidence and predictors of definite stent thrombosis after coronary stent implantation. Chin Med J (Engl). 2012 May; 125(9):1547-51.
-
Calvin JE, Shanbhag S, Avery E, Kane J, Richardson D, Powell L. Adherence to evidence-based guidelines for heart failure in physicians and their patients: lessons from the Heart Failure Adherence Retention Trial (HART). Congest Heart Fail. 2012 Mar-Apr; 18(2):73-8.
-
Al-Khudari S, Loochtan MJ, Peterson E, Yaremchuk KL. Management of angiotensin-converting enzyme inhibitor-induced angioedema. Laryngoscope. 2011 Nov; 121(11):2327-34.
-
Nijenhuis T, Sloan AJ, Hoenderop JG, Flesche J, van Goor H, Kistler AD, Bakker M, Bindels RJ, de Boer RA, M?ller CC, Hamming I, Navis G, Wetzels JF, Berden JH, Reiser J, Faul C, van der Vlag J. Angiotensin II contributes to podocyte injury by increasing TRPC6 expression via an NFAT-mediated positive feedback signaling pathway. Am J Pathol. 2011 Oct; 179(4):1719-32.
-
Arif SA, Mergenhagen KA, Del Carpio RO, Ho C. Treatment of systolic heart failure in the elderly: an evidence-based review. Ann Pharmacother. 2010 Oct; 44(10):1604-14.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|